{"name":"Lei Lei, MD","slug":"lei-lei-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Concerta","genericName":"Concerta","slug":"concerta","indication":"Attention deficit hyperactivity disorder","status":"marketed"}]}],"pipeline":[{"name":"Concerta","genericName":"Concerta","slug":"concerta","phase":"marketed","mechanism":"Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor","indications":["Attention deficit hyperactivity disorder","Narcolepsy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOckpwcFBFWXQ4OVBveVdVWm9NRmtHQ0Fnay00X3E5aUVKdEZiYkdKb254WlNGTnRUNmJqTS1VSnhnaXpnQnh6eDVqamFvVXRQVGFsYjZ5Q3Z5U2hhWXFLVHR3dmR4eVlIUDQ5T3RQQ2ptai1xb2ZaaE1MU0x2a0ltRzJKQzFPU3lTeUJYOHRuVm9pNk9wWnNhalNqRVJOTkh6VjgzUmJkbzEzaExvQlppVjhoLWtZUzA3WTNHcVdEd0txZw?oc=5","date":"2026-04-03","type":"pipeline","source":"businesswire.com","summary":"Innate Pharma to Participate in the Kempen Life Sciences Conference - businesswire.com","headline":"Innate Pharma to Participate in the Kempen Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPWU5GMDh1d044bUtDQVJQRFM4Z1BuRzN4b1U3OGVfUmJySjUtMVVDdFNhS0JoT2hiczluV0VacURiQjdkdGEybW9jQzlLbGlvSlVVRFdXNEJ6S1VXdl8yNi1DWmNoclF5MGQwUHZLc0psd2NkV2o5UFNVZ25FSHJlY000UXFYTlZheXNkODl5cVllODB6eksxbHFDa1cxdmZEVzVNWUJXeTBoUEZ6TEFZMHdjSGxCblpvZVZvR0FNNGlXUXVaVnV4cEtIaFp4MGVCck42NnRWLWxnd3pxa3kyTnVhRk1US2NBM2RCRzB4U2JiM2piTzJRUWtkdHJuYTU0cEk0TTZuaXlQbWZLZXJETk9FYw?oc=5","date":"2026-04-02","type":"pipeline","source":"businesswire.com","summary":"Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report - businesswire.com","headline":"Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f An","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNWDJpZVhPcFZEM3BDQW5WbmFmazJkeTEtMXE1cmdBS25sYXZOeC1mOGdlTFN2ZTFnbXNQcW1vMnBJNEJ0c0ZCU016ZUtCdERRLUkwb0JzWWkzQ1otaXAxTC1HQXlGWmFXYm1ha1cxQjItLTFFZ1Ywbk9JbkZGRlkxbGRKZjRPTjI5VHBZNmY2dHZrMHNrcTgwMlBrcXJ4dG9vcHRvODVyOW5fUkZRcTdkR0QzUF9LZm9mOXdNQWtpbkQ3NmxDUEY4elc2MzRpZy1XR2ZSaVkyUEt4djl3NkE?oc=5","date":"2026-03-19","type":"pipeline","source":"businesswire.com","summary":"Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results - businesswire.com","headline":"Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSDMyVDJRek5PQ0lOeGVKMUpzb2RGZmRONFBId2F5TEpOVVJkckowT084TGIwUDBlRDNKS2FMN0xOTngwZGIzSzZkN1JFS0p2SHRjeldwV1I0aVRYa3p2NzVncjBCcFNYMl9MNE4xMzlMaS1UeGF5aWJZTEx5LW5zNV9yazZQS2ozUlhpYkVHdkN3WC1IS0VjZDVRMnd1a2xubmZMNlhOZ3phNmJmSzRodzFqX2RNWFVNX25QM1FVUFJiZzZtSlgzUGY5VlRjZUp5MVZCTg?oc=5","date":"2026-02-18","type":"deal","source":"businesswire.com","summary":"Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - businesswire.com","headline":"Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZHRrY1EwWmF1SlJfVGk1NjJZQjdmc0lWTmJhamliV3hBZVpWVWoyZlJkU3lUazVmTDVIUm9jWFh2QkJGbnIwYVk3Ym5DNjZoTi1lbjZpR3QzeUlIckFTYkNpblZEQkdhS1BCNTV1Nm5oaEdLUDBRNThIOGpaekJiOHlyRHJhanpUaUxSUzRsSnc4ejlF?oc=5","date":"2025-12-11","type":"pipeline","source":"BioSpace","summary":"Innate Pharma Releases Its 2026 Financial Calendar - BioSpace","headline":"Innate Pharma Releases Its 2026 Financial Calendar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQY3k1elFUUTVscUM0TUF6ZW84b0xyNmliYjZsWGcxQXBIWC1OSmZmekhBN2hvWTF6OXJsUDZrZEJaRVZHaDZGVFlTRzF4Q1ByYW1tclN5aXBvclVWMzZBb2pXVWc5ZjEtbExnZHV3amhyRy1ReXNiYThwcGxweGVMNUZFeEZNUVlXd3NUUFVGQ2xKdFpQd25DLXZCMjh1emFTTDZHbTFpYU1paFlqU3hJVzR6SE16VGd3MkxPOEg4NmdVdjBJRWc?oc=5","date":"2025-10-27","type":"regulatory","source":"Fierce Pharma","summary":"Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study - Fierce Pharma","headline":"Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5NNzB6VVVGcC1WZ2hYT2ItZlFmZlZWU1lIZGZfOHpaMzYwdVoyRUJzbEYzSWpTWUwwOVBVR1hlTDA1ejNDdFJ1enV4aGt6UWxYWEZPeG5yU210X0pPNUhz?oc=5","date":"2025-08-20","type":"pipeline","source":"Nature","summary":"Drug screening in pharmaceutical and forensic applications using extractive-liquid sampling electron ionization-mass spectrometry (E-LEI-MS) - Nature","headline":"Drug screening in pharmaceutical and forensic applications using extractive-liquid sampling electron ionization-mass spe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQN3M5a2lIVmNCbHppUzhQQjZRZklHT0FJQjZpaU1CaGo5cFp2dDhFUzh5Q2N4OVNFMWYwVnA0Tzg5T1VJMUdGYUZ5a3lXRGxRbWE4ZlFSOFNrakdmYUYxSjNmcWFkbG4zeFpWUDJ0dTFMclJWczl3ajh0alN2QlRUeQ?oc=5","date":"2025-08-14","type":"pipeline","source":"logos-pres.md","summary":"Meditrina Pharmaceuticals has changed owners - logos-pres.md","headline":"Meditrina Pharmaceuticals has changed owners - logos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9VRjBIMWNudWNjcmxzWldOZnljRFNxUkNpTVlmOUhWb0k1QzJCYWVBYnR1ektPSzRBQnppbFFrSXdkUGJTcjVjWXlEbUdTY215Yk94em5vaDFnQ0dXVm1ZMUloaGVJQmhyLUsyRGhtRjBXUQ?oc=5","date":"2025-06-29","type":"deal","source":"logos-pres.md","summary":"Farmaco is preparing for a merger - logos-pres.md","headline":"Farmaco is preparing for a merger - logos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNbi1mOTFmTzk1cExCVGhsbHg5T1FxRTBPNWlhcENUQnFyYkswa1NjNnhSU2RwV1BPZFVBR291NXRwY1FBMVdkUTFWTjRVSldUa1VQMHhTVXpiWkxRcUtNMzNxOGt6SUxwaE1yVndLZm13Z01aTmpnMWpPSDNUYURFTXRMX3JGTGdVaTR4aFFuNmlHcGlv?oc=5","date":"2025-01-29","type":"pipeline","source":"Frontiers","summary":"Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II - Frontiers","headline":"Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume I","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9wUnFIRTR0LVNkUko3VE5FbG1qcVdhN3RwQXlEck1SV3FrcHhwVENZOTBlUmdUbGwzdGNmTlRtcC1teFczSDhoQ2tDREJOZGdXcmU4SDNPYzNpNUNoc2ZpamNySk5DTDFsdEVxMjlWZHBXZw?oc=5","date":"2024-09-03","type":"pipeline","source":"Wiley","summary":"Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers - Wiley","headline":"Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rif","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9oQTBVMjNuWHFTRVVWbjVnejEzVVVSZk0xUk9zZHJVanoyTzB3djN3M0RsUGh3RnpmcHY2RTNud3ZBXzFhZHlUb19qS0xzZHZUeV9kemFJeWxjU3dVeTBF?oc=5","date":"2018-06-25","type":"pipeline","source":"NEJM","summary":"Cytochrome P-450 Polymorphisms and Response to Clopidogrel - NEJM","headline":"Cytochrome P-450 Polymorphisms and Response to Clopidogrel","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":9,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}